SCHEMBL1860665

SCHEMBL1860665

O=C1c2ccccc2C(=O)N1CC#CCn1ccc([N+](=O)[O-])n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2D6 P10635 1/20 0.42
GAA P10253 3/20 0.41
PKM P14618 2/20 0.40
POLB P06746 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
F2 P00734 1/20 0.38
PLAU P00749 1/20 0.38
KLKB1 P03952 1/20 0.38
ELANE P08246 1/20 0.38
TYR P14679 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
DRD5 P21918 1/20 0.38
P2RY6 Q15077 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1393184 0.82 ALDH1A1 (0.45) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL1868398 0.77 PKM (0.48) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL12633734 0.77 KMT2A (0.45) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL1859213 0.77 PKM (0.45) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL21825637 0.72 PKM (0.48) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL1866232 0.68 F2 (0.49) ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL1862779 0.67 ALDH1A1 (0.49) ALDH1A1GAAPOLBSMN1; SMN2NPSR1
SCHEMBL10851246 0.67 ALDH1A1 (0.52) ALDH1A1GAAPKMPOLBSMN1; SMN2
SCHEMBL4632890 0.67 ALDH1A1 (0.49) ALDH1A1GAAPKMPOLBSMN1; SMN2
SCHEMBL6357561 0.67 DRD3 (0.51) ALDH1A1GAAPOLBSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935699-B2 Pyrazole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2011-05-03 US disclosed
EP-2261216-A2 Pyrazoles as glucokinase activators F. Hoffmann-La Roche AG (CH) 2010-12-15 EP disclosed
EP-2046755-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. Hoffmann-Roche AG (CH) 2009-04-15 EP disclosed
WO-2008012227-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-31 WO disclosed
US-20080021032-A1 Pyrazole glucokinase activators BERTHEL STEVEN JOSEPH 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021032-A1 Pyrazole glucokinase activators GCKR, GCK, GALK1 ALDH1A1 1567/4885CYP1A2 901/4885CYP3A4 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.